Hyponatremia in Acute Stroke: To Treat or Not to Treat?

Hyponatremia is the most common electrolyte disorder both in hospitalized patients and individuals from the community with a reported incidence mounting up to 30% and 8%, respectively.1,2 Its association with increased risk of mortality has been well-established.3-5 Several meta-analyses have demonstrated that hyponatremia increases mortality in patients with common clinical conditions, such as acute myocardial infarction, heart failure, cirrhosis, and chronic kidney disease,3-5 while “correction” of serum sodium levels improves survival.
Source: Journal of Stroke and Cerebrovascular Diseases - Category: Neurology Authors: Tags: Letter to the Editor Source Type: research

Related Links:

This study provides a framework for combined metabolomics analysis of this mouse model lacking the capacity for selenocysteine decomposition.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Mus musculus Source Type: research
ConclusionsTraffic light and red stop sign warning labels significantly reduced sodium ordered compared with a control. Warning labels also increased knowledge about high sodium content in restaurant meals. Designs with warning text are likely to improve consumer understanding.
Source: American Journal of Preventive Medicine - Category: International Medicine & Public Health Source Type: research
ConclusionCongruence between physical and affective symptom clusters should be considered when identifying patients at higher risk for poor outcomes.
Source: Heart and Lung: The Journal of Acute and Critical Care - Category: Respiratory Medicine Source Type: research
Phase III VICTORIA study with vericiguat in patients with worsening chronic heart failure meets primary endpointVericiguat reduced the risk of cardiovascular death or heart failure hospitalization versus placebo when given in combination with available heart failure therapies / Vericiguat is the first-in-class soluble guanylate cyclase stimulator being developed to treat patients with worsening chronic heart failuremehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news
Liver cirrhosis (LC) is the final usual outcome of liver damage induced by various chronic liver diseases. Because of asymptomatic nature of LC, it is usually diagnosed at late and advanced stages, and patients are easy to miss the best timing for treatment. Thus, the early detection of LC is needed. In the prospective Korean Cancer Prevention Study-II (K-II), we aimed to identify valuable biomarkers for LC using metabolomics to distinguish subjects with incident LC (LC group) from subjects free from LC (control group) during a mean 7-year follow-up period. Metabolic alterations were investigated using baseline serum speci...
Source: Frontiers in Physiology - Category: Physiology Source Type: research
AbstractWhile searching for novel anti-echinococcosis drugs, we have been focusing on glycolysis which is relied on byEchinococcus for energy production and intermediates for other metabolic processes. The aim of this study was to investigate the potential therapeutic implication of glycolytic inhibitors onEchinococcus. Our results demonstrate that at an initial concentration of 40  μM, all inhibitors of glycolysis used in the current experiment [3-bromopyruvate (3-BrPA), ornidazole, clorsulon (CLS), sodium oxamate and 2,6-dihydroxynaphthalene (NA-P2)] show considerable in vitro effects againstEchinococcus granulos...
Source: Veterinary Research - Category: Veterinary Research Source Type: research
CONCLUSIONS: From this case report, the authors believe NPWTi-d may be more effective in cases with intractable ulcers associated with infection that need better granulation. PMID: 31730514 [PubMed - in process]
Source: Wounds - Category: General Medicine Tags: Wounds Source Type: research
Publication date: Available online 17 November 2019Source: Pharmacological ResearchAuthor(s): Qiujin Jia, Lirong Wang, Xiaonan Zhang, Yuejia Ding, Hao Li, Yingxi Yang, Ao Zhang, Yanyang Li, Shichao Lv, Junping ZhangAbstractIn recent years, although the concept and means of modern treatment of chronic heart failure(CHF) are continually improving, the readmission rate and mortality rate are still high. At present, there is evidence that there is a link between gut microbiota and heart failure, so the intervention of gut microbiota and its metabolites is expected to become a potential new therapeutic target in heart failure. ...
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
HEART attack is a sudden and distressing event that requires immediate medical attention to prevent a potentially fatal complication. While symptoms tend to show up in the immediate run up to having a heart attack, they can also occur a month or even earlier - here are five warning signs.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
The inflammation-fighting drug colchicine, already a treatment for gout, dramatically reduces the odds of future cardiovascular problems in people who have just survived a heart attack, a large new study by a Montreal researcher has concluded.
Source: CBC | Health - Category: Consumer Health News Tags: News/Health Source Type: news
More News: Cardiology | Chronic Kidney Disease | Cirrhosis | Heart | Heart Attack | Heart Failure | Neurology | Sodium | Stroke | Urology & Nephrology